Collateral Ventilation
Collateral ventilation can limit the effectiveness of endobronchial lung volume reduction therapy for severe emphysema.1,2 Recently presented data has shown the predictive value of Chartis System’s assessment of collateral ventilation3,4 and its importance in treatment planning for EBV therapy. Without accurate assessment of collateral flow within the targeted treatment area, physicians have difficulty predicting whether even the most carefully selected patient will respond to EBV treatment.
| NO COLLATERAL VENTILATION (CV-) |
COLLATERAL VENTILATION (CV+) |
| The Chartis System detects a low level of collateral ventilation. The expiratory flow in the lung compartment is reduced over several breathing cycles, indicating little to no collateral airflow from adjacent lung compartment(s). |
The Chartis System detects a high level of collateral ventilation. Expiratory airflow persists over time, indicating the presence of collateral airflow from adjacent lung compartment(s). |
Data-driven treatment planning
The combination of the Chartis System and Zephyr valve therapy offers emphysema patients a promising option for endobronchial lung volume reduction. Pulmonx’s unique approach to management of hyperinflation provides physicians with real-time, accurate physiologic information to guide treatment decisions.4
Footnotes:
1. Aljuri N, Freitag L. Validation and pilot clinical study of a new bronchoscopic method to measure collateral ventilation prior to endobronchial lung volume reduction. J Appl Physiol. 2009;106:774-783.
2. Fessler HE. Collateral damage assessment for endobronchial lung volume reduction. J Appl Physiol. 2009;106:755-756.
3. Gompelmann D, et al. Predicting Atelectasis by Assessment of Collateral Ventilation prior to Endobronchial Lung Volume Reduction: A Feasibility Study. Respiration (DOI:10.1159/000319441), Published Online: July 21, 2010.
4. Use of Chartis Pulmonary Assessment System to Optimize Subject Selection for Endobronchial Lung Volume Reduction (ELVR) - Chartis Multi-Centre Study, data presented at ATS2011. Data on file with Pulmonx, Inc.
Zephyr® EBV is an Investigational Device in the United States. Limited by U.S. law to investigational use. Chartis® system is for use/sale outside the U.S. only.
